INS and type 2 diabetes mellitus: A placebo-controlled clinical study conducted by Merovci et al., reported that two-weeks treatment with dapagliflozin in patients with uncontrolled T2DM not only improved insulin sensitivity (based on euglycaemic clamp), but also led to an improved β-cell function, calculated as the ratio between the change in C-peptide and the change in glucose values during a 2 h OGTT [20].